Ascendis Pharma Shares Dip 1.53% as 73.74% Volume Surge Propels 490th Ranking Analysts Hike Price Targets Amid Competitive Pressures and FDA Decision Loom

Market Snapshot

Ascendis Pharma (ASND) closed February 12, 2026, with a 1.53% decline in its stock price, trading at $218.05 per share. Despite the drop, the stock saw a surge in trading volume, with $0.37 billion in turnover—a 73.74% increase from the previous day—ranking it 490th among stocks by trading activity. The company’s revenue growth over the past 12 months reached 97.46%, supported by a strong gross profit margin of 86.8%, but its fourth-quarter 2025 results fell short of expectations, reporting a loss of -$0.55 per share (vs. -$0.15 anticipated) and revenue of €240 million (vs. €245.68 million forecasted).

Key Drivers

Analyst Optimism and Price Target Hikes

Multiple analysts have raised price targets for Ascendis Pharma in recent weeks, signaling confidence in its long-term potential despite near-term challenges. Cantor Fitzgerald increased its price target to $300 from $254, maintaining an Overweight rating, while Stifel raised its target to $325 from $256, keeping a Buy rating. These adjustments reflect analysts’ views that the stock is undervalued at current levels, with a 75.59% return over the past year. The upgrades also highlight optimism about the growth of Yorvipath and the potential of combination therapies involving Skytrofa, such as the COACH trial, which physicians see as a “new benchmark.”

Competitive Pressure from BridgeBio’s Infigratinib

Ascendis faces heightened competition following positive Phase 3 results for BridgeBio’s infigratinib in achondroplasia. The oral drug demonstrated significant improvements in height velocity and body proportionality compared to placebo, potentially challenging Ascendis’s TransCon CNP, which awaits an FDA decision by February 28. Cantor Fitzgerald and others argue that this competitive development could act as a “clearing event” for Ascendis shares, shifting focus to the combination therapy potential of TransCon CNP with Skytrofa. However, the stock dipped following BridgeBio’s results, underscoring market sensitivity to competitive threats.

Mixed Financial Performance and Earnings Disappointment

Ascendis’s fourth-quarter 2025 results revealed a larger-than-expected loss per share (-$0.55 vs. -$0.15) and slightly below-forecast revenue (€240 million vs. €245.68 million). While the company’s revenue growth of 97.46% over the past year and robust gross profit margins (86.8%) demonstrate operational strength, the earnings miss raised concerns about its ability to sustain profitability. Analysts like Stifel remain bullish, citing Yorvipath’s growth trajectory as a key driver for 2026, but the mixed results contributed to short-term investor caution.

Upcoming FDA Decision and Strategic Shifts

The FDA’s decision on TransCon CNP’s approval by February 28 is a pivotal event for Ascendis. If approved, the drug could access a multi-billion-euro market for achondroplasia treatment. Cantor Fitzgerald and others suggest the narrative for TransCon CNP should pivot toward combination therapies, such as pairing it with Skytrofa, to unlock broader therapeutic value. Meanwhile, the company’s cash position of €539 million and self-sustaining business model reduce dilution risks, enabling continued investment in its pipeline. However, the competitive landscape and regulatory uncertainties remain critical risks.

Analyst Divergence and Market Sentiment

While most analysts maintain positive ratings, there is divergence in price targets. The consensus target price has risen to $307.33 from $270.50 over the past year, but Bank of America’s Tazeen Ahmad set a more conservative $161 target. This disparity reflects differing views on the impact of competition, regulatory outcomes, and the company’s ability to execute on its combination therapy strategy. Despite the upgrades, the stock’s 1.53% decline on February 12 highlights market sensitivity to near-term risks, including BridgeBio’s progress and the FDA’s decision.

Conclusion

Ascendis Pharma’s stock performance is shaped by a blend of optimism and caution. Analyst upgrades and the company’s strong revenue growth underscore long-term potential, particularly in combination therapies and the TransCon CNP franchise. However, near-term challenges—including competitive threats from BridgeBio, earnings disappointments, and regulatory uncertainty—have weighed on investor sentiment. The FDA’s decision on TransCon CNP and the success of combination trials will be critical in determining whether the stock can sustain its upward trajectory or face renewed pressure from market skepticism.